XML 62 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stockholders' Equity (Tables)
12 Months Ended
Jun. 30, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Activity of Restricted Stock Units
The following table summarizes the activity of RSUs, including PRSUs, during year ended June 30, 2024 (in thousands, except years and per share amounts):
Restricted
Stock
Units
Weighted
Average
Grant-Date
Fair Value
Weighted
Average
Remaining
Contractual
Term in Years
Outstanding at beginning of period762 $227.82 1.7
Granted674 148.55 
Vested*(236)215.74 
Forfeited (61)218.09 
Outstanding at end of period1,139 $183.93 1.6
*Includes 60 thousand shares netted for tax.
Schedule of Option Activity
The following table summarizes option activity during the year ended June 30, 2024 (in thousands, except years and per share amounts):
OptionsWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term in Years
Outstanding at beginning of period881 $134.52 3.0
Granted73 148.90 
Exercised*(166)81.76 
Forfeited(2)232.16 
Outstanding at end of period786 $146.90 2.8
Options exercisable at end of period633 $136.06 2.1
Options vested and expected to vest at end of period778 $146.52 2.8
*Includes 1 thousand shares netted for tax.
Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted
We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June 30, 2024, 2023 and 2022:
202420232022
Stock options:
Weighted average grant date fair value$50.48$74.95$72.16
Weighted average risk-free interest rate4.44%3.85%1.29%
Expected life in years4.94.94.9
Dividend yield1.29%0.78%0.66%
Expected volatility36%34%32%
ESPP purchase rights:
Weighted average grant date fair value$47.40$52.38$50.46
Weighted average risk-free interest rate5.4%3.6%0.3%
Expected life in years6 months6 months6 months
Dividend yield
0.75% - 1.30%
0.75% - 0.84%
0.63% - 0.98%
Expected volatility
27% - 40%
27% - 34%
20% - 34%
Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized
The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June 30, 2024, 2023 and 2022 (in thousands):
202420232022
Cost of sales $7,563 $6,465 $5,218 
Selling, general and administrative expenses58,149 53,049 50,791 
Research and development expenses14,472 11,628 9,248 
Stock-based compensation costs80,184 71,142 65,257 
Tax benefit(15,053)(24,860)(29,262)
Stock-based compensation costs, net of tax benefit$65,131 $46,282 $35,995